His cardiologist and ophthalmologist advised he continue using Lucentis after he suffered two heart attacks.
Lucentis comparison in early May, and news reports claim they have found safety concerns.
Since Genentech first announced its success with Lucentis two months ago, Eyetech shares have plummeted.
It's not clear whether any conclusions can be drawn comparing Macugen to Lucentis, he argues.
Notably, 2Q was the first full quarter post Lucentis approval in DME in Jan-2011.
To resolve the debate, the federal National Eye Institute plans a giant Avastin-versus-Lucentis head-to-head trial.
Goddard says that even with competition from Lucentis, he sees real opportunities for Macugen.
So, noting the way in which the drug was being used and was successful Lucentis arrives.
FORBES: Avastin v. Lucentis: it's the Licence and Patent System, Stupid!
But the primary care trust (PCT) says recently reduced costs in manufacturing Lucentis now make it more affordable.
Both are randomized trials to test the effectiveness of Avastin against Lucentis in treating people with wet AMD.
FORBES: Blinded By Savings? Is Cost Trumping Risk On Blindness Drug?
The excellent growth in this Q was primarily due to EU approval for Lucentis in Diabetic Macular Edema.
Lucentis is a prescription drug for the treatment of patients with wet age-related macular degeneration and macular edema.
Friedlander's stem-cell therapy could one day compete with drugs like Lucentis from Genentech.
Genentech announced on May 23 that Lucentis helped maintain a gain of vision.
However, Lucentis is much more expensive than Avastin so why pay the extra?
FORBES: Avastin v. Lucentis: it's the Licence and Patent System, Stupid!
The story everyone's writing is this: Genentech's being hurt by weakening sales of Lucentis, its drug for age-related macular degeneration.
Will it continue to do so if the research says Avastin and Lucentis are equally effective, or even pretty close?
However, Lucentis is much more expensive than the non-AMD approved Avastin, and that raises concerns about the poor and uninsured.
FORBES: Avastin vs Lucentis: One Step Closer to Cost Rationing?
Tony Watson, 69, is blind in one eye and wants the drug Lucentis to save the sight in his other eye.
Would a decision not to cover Lucentis harm patients who are benefiting significantly from it, even reversing the loss of sight?
Lucentis is actually a fragment of Avastin, developed by the same Genentech chemist who created the cancer blockbuster, Napoleone Ferrara .
When Lucentis was launched, it shocked Wall Street with its efficacy and basically put Genentech's main competitor, Eyetech's Macugen, out of business.
The other, Lucentis, was limited to a particular category of individuals with the disease, restricting it to about one in five sufferers.
Is there room for another eye drug that works much like the already available medicines Lucentis and Avastin, both made by Roche?
Lucentis studies are important because they raise questions about safety and efficacy.
The National Institute for Health and Clinical Excellence (NICE) approved Lucentis, an anti-VGEF medciation, for use in England and Wales in 2008.
Macugen could face a rough patch as Lucentis is launched, Goddard admits.
Not long after, the board offered to pay for Tagg's Lucentis treatments.
With the help of evidence compiled by the RNIB and his specialists, Mr Watson eventually convinced health bosses to fund his Lucentis injections.
The face off between Lucentis and Avastin may well become moot given the pricing of new treatments for wet AMD, such as Eylea.
FORBES: Blinded By Savings? Is Cost Trumping Risk On Blindness Drug?
应用推荐